ANG Lifesciences India Ltd. Stock Analysis 540694.BO

ANG Lifesciences India Ltd. engages in the manufacture and marketing of finished pharmaceutical formulations in a form of sterile dry powder for injection vials. The company is headquartered in Amritsar, Punjab and currently employs 412 full-time employees. The company went IPO on 2017-09-08. The firm is engaged in the business of manufacturing and marketing of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials. The company operates in two segments, namely pharmaceuticals and printing and packaging. The firm's product portfolio includes various products comprising therapeutic categories, such as Antibiotics, Antiviral, Antimalarial, Antiulcer, Carbapenem, Corticosteroid, Penicillin and Beta Lactamase Inhibitor. The Company’s product category includes Dry Powder Injection, Liquid Injections, Hard Gelatin Capsule, Tablet Beta Lactum, Tablets, Liquid Suspension /Syrup, Ointment/Creams, and Soft Gelatin Capsule. Its Dry Powder Injection products include Ampicillin & Cloxacillin for injection 500mg, Azetronam for Injection USP 500mg, Ampicillin Injection 1.0gm, Ceftriaxone Injection 250mg, Amoxycillin & Potassium Clavulanate for injection 1.2gm, and others.